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tween  6 80% vs.  ! 80% adherence, but compared to  ! 65% 
adherence, pill adherence levels of  6 90 to  ! 99% (HR 0.56, 
95% CI = 0.34–0.91; p = 0.02) and  6 99% (HR 0.46, 95% CI = 
0.29–0.73; p = 0.001) were associated with lower occurrence 
of the combined outcome at 18 months.  Conclusions: Long-
term excellent adherence to non-specific pill prescription 
among ischemic stroke patients is independently associated 
with lower vascular risk, and is likely a marker of overall 
healthy behavior that may be helpful in targeting stroke pa-
tients with unhealthy practices. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Although several studies have shown that medications 
and lifestyle modification can improve outcomes after 
stroke and TIA  [1] , adherence to these interventions is 
unfortunately sub-par  [2, 3] . Not surprisingly, poor ad-
herence tends to limit the effectiveness of proven thera-
pies, resulting in lost opportunities to reduce vascular 
risk after stroke  [4] . However, adherence itself may reflect 
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 Abstract 
 Background: Adherence to non-specific prescription thera-
py may be associated with clinical outcomes beyond a given 
treatment effect. We assessed the association of blinded 
randomized pill prescription adherence with vascular out-
comes after ischemic stroke.  Methods: We analyzed the 
 Vitamin Intervention for Stroke Prevention (VISP) study da-
tabase. VISP was a double-blind randomized trial, designed 
to determine whether high doses of vitamins (vs. low doses) 
would reduce recurrent stroke risk in 3,680 participants over 
a 2-year period. We examined the independent association 
of adherence with a composite endpoint (stroke, myocardial 
infarction, death).  Results: Among 3,357 (91%) subjects with 
complete data, women, non-White persons, current smok-
ers, those not on statins and those without a history of coro-
nary artery bypass surgery were significantly less likely to be 
optimally adherent. Over the trial, persons who adhered well 
to treatment were less likely to experience the combined 
outcome than those who adhered poorly (13.4 vs. 20.6%,
p  ! 0.0001). After multivariable analysis using various adher-
ence measures, there were no significant differences be-
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compliance with other types of conduct that influence 
clinical outcome  [5] . In other words, adherence may be 
more than just taking a pill  [5] . Indeed, data from ran-
domized clinical trials in cardiac patients indicate that 
the advantage associated with better adherence might be 
unrelated to the effect of a specific treatment  [6–8] . For 
instance, it has been shown in coronary artery disease 
(CAD) and congestive heart failure patients that im-
proved adherence, even to placebo, is associated with im-
proved survival and fewer cardiovascular events  [6–8] .
 The aforementioned findings suggest that a better un-
derstanding of the impact and nature of adherence on 
clinical outcomes could provide an avenue for novel in-
terventions geared at optimizing adherence  [5] . Little if 
anything is known about the relationship between non-
specific pill adherence and clinical outcomes among pa-
tients with established cerebrovascular disease. Since pill 
compliance is routinely recorded in randomized second-
ary stroke prevention trials, assessing its association with 
meaningful endpoints could provide some insight into 
this issue.
 The objective of this study was to determine whether 
greater adherence to blinded randomized pill prescrip-
tion within a stroke prevention trial, regardless of treat-




 We reviewed data from the Vitamin Intervention for Stroke 
Prevention (VISP) trial  [9] . The VISP trial was a multicenter dou-
ble-blind randomized controlled clinical trial performed at cen-
ters across the USA (n = 45), Canada (n = 10) and Scotland (n = 
1). It was designed to determine whether the best medical therapy 
and a multivitamin containing high-dose folic acid, pyridoxine, 
and cobalamin given to lower total homocysteine levels would 
reduce the incidence of recurrent cerebral infarction in patients 
with a non-disabling cerebral infarction  [9] . The methods and 
results of this trial have previously been described  [9] . Pertinent 
to the current report, the VISP population comprised persons 
whom neurologists had identified as having experienced an isch-
emic stroke from September 1996 through May 2003. Demo-
graphic, clinical, and laboratory data were collected at baseline, 
with subsequent clinical and laboratory information obtained in 
follow-up visits at 6, 12, 18, and 24 months.
 Variables 
 Independent Variable. We took account of the date on which 
the pills were distributed in our measure of adherence. Adherence 
was calculated at each clinic visit as [(number of pills taken by the 
participant subtracted from number of pills distributed to the 
participant) divided by number of days since the last scheduled 
visit at which pills were dispensed] multiplied by 100. We trimmed 
any adherence values over 100 to 100%; negative adherence values 
were considered invalid and set to missing. Assessments at the
6-, 12-, and 18-month clinic visits were included here for the par-
ticipants who had at least one such assessment. Not all patients 
had all these assessments. In all but one of our analyses of adher-
ence, measurements of adherence made after a stroke or coronary 
event were excluded. Several summary measures of adherence 
were considered. Total pill adherence was defined as: (number of 
visits at which adherence was  1 80% divided by number of visits 
with adherence data) multiplied by 100. Adherence  6 80% at each 
measure was deemed good. Adherence was analyzed in 4 ways: (1) 
as a dichotomized variable (adherence  6 80% at each visit, yes vs. 
no  [5] ); (2) average overall adherence over the whole study  6 80% 
(yes vs. no); (3) average overall adherence of measures made prior 
to an event ( 6 80%, yes vs. no); (4) visit-specific survival analyses, 
using multiple categories ( ! 65%, 65% to  ! 80%,  6 80% to  ! 90%, 
 6 90% to  ! 99%, and  6 99%) for persons event-free until an index 
visit.
 Dependent Variable. The endpoint for this particular analysis 
was a composite outcome comprising the occurrence of stroke, 
myocardial infarction or death from any cause.
 Covariates. We included a baseline history of any symptom-
atic (‘hard’) vascular event, baseline vascular biomarkers, and fac-
tors previously associated with adherence as covariates. This in-
cluded categorical variables (sex, race, history of ischemic stroke 
prior to randomization, smoking, and statin use) and continuous 
variables (age, systolic blood pressure, and fasting total choles-
terol)  [1, 5] . Since there were no specific measures of CAD prior to 
randomization and several other symptomatic cardiac conditions 
can impact upon mortality, we also included a history of any of the 
following as covariates: angina, myocardial infarction, congestive 
heart failure, coronary artery bypass surgery, and coronary angio-
plasty or stenting. We also included VISP assignment group (i.e. 
high-dose vs. low-dose vitamin treatment) as a covariate.
 Statistical Analysis 
 Multiple logistic regression was used in the analysis of the as-
sociation between overall adherence and outcome. Cox propor-
tional hazard models were used in the analysis of the association 
between visit-specific adherence and time to outcome.
 Results 
 A total of 3,680 ischemic stroke patients were enrolled 
during the study period.  Figure 1 shows a breakdown of 
the exclusions and resulting counts of participants, leav-
ing 3,357 subjects who had complete and verifiable data. 
Of these, the mean and median ages (at baseline visit) 
were 66.4 and 67 years, respectively; 38% were female, 
81% White, and 14% African-American.
 Women, non-White persons, current smokers, those 
with no history of coronary artery bypass surgery, and 
individuals not on statin treatment were less likely to be 
optimally adherent to prescription pill treatment ( ta-
ble 1 ).
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 Unadjusted analyses of the combined outcome over 
the course of the trial, including adherence measures ob-
tained after a stroke or coronary event, revealed that 
those who adhered well ( 6 80%) to treatment at each as-
sessment visit over the trial period were less likely to ex-
perience the outcome than poor adherers (13.4 vs. 20.6%, 
p  ! 0.0001). Similar results were obtained with unadjust-
ed analyses of the outcome by total average overall pill 
adherence over the duration of the trial  6 80% or not. 
However, when we excluded all visits that occurred after 
an event (i.e. only visits preceding the occurrence of an 
outcome were considered): 11.4% of those with an average 
adherence  6 80% experienced an outcome versus 12.0% 
of those with adherence  ! 80% (p = 0.73). When this as-
sociation was adjusted for potential confounders through 
logistic regression, the association remained non-signifi-
cant.  Table 2 displays the frequencies of total study pre-
scription pill adherence (before vascular event) by study 
time point and primary endpoint.
 When the analysis was performed as study-visit spe-
cific, including only those with no outcome prior to the 
index visit when adherence was assessed, unadjusted 
analyses showed no significant association with adher-
ence up to the 6-month visit ( table 3 ), but significant as-
sociations with adherence through the 12- and 18-month 
visits ( tables 4 and  5 ).
 After adjustment for the basic confounders of age, sex, 
race, and study treatment, study pill adherence  6 90% 
(vs.  ! 65%) at the 12-month and 18-month study visits was 
significantly associated with a lower occurrence of the 
composite endpoint (p  ! 0.05); however, no significant 
association was found between study pill adherence and 
outcome at the 6-month visit. The results of more expan-
sive multivariable modeling showed similar results and 
can be found in  tables 3–5 . There were no significant out-
come differences by pill adherence at the 6-month visit 
( table 3 ). However, study subjects who adhered to pill pre-
scription at the 12-month and 18-month visits either 90% 
to  ! 99%, or  6 99%, of the time (compared to  ! 65%), were 
significantly less likely to have experienced the composite 
endpoint. There were no significant interactions between 
study pill adherence and VISP treatment, nor any sig-
nificant associations between VISP treatment and the 
composite endpoint.
 Discussion 
 In this secondary analysis of a clinical trial dataset, we 
found that excellent adherence to study pill prescription 
(i.e.  6 90% of the time), regardless of treatment assign-
ment, among individuals with a recent ischemic stroke, 
was independently associated with lower risk of future 
major vascular events at 12 and 18 months after enroll-
ment, but not at 6 months after enrollment. Contrary to 
our initial hypothesis, good adherence (i.e.  6 80% of the 
Start: 3680 participants
Remainder: 3357 participants
>80% adherence: 2785 (82.9%) participants* ≤80% adherence: 572 (17.0%) participants*
34 subjects with no follow-up data removed
190 subjects with no vitamin adherence data removed
99 subjects with vitamin adherence data collected  
outside stipulated time windows removed
*Overall study pill adherence Fig. 1. Exclusions and resulting counts of 
study participants. 
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time) was not associated with outcome. Since the favor-
able clinical effects of excellent adherence were seen 
across treatment groups without any interaction of ad-
herence with VISP treatment, these benefits were likely 
derived beyond the biological properties of the therapies 
themselves. An independent link between adherence to 
study pill prescription (including placebo) and clinical 
outcomes has been shown in several studies of persons 
with cardiac disease  [5] , but we are unaware of any stud-
ies that have explored this issue among stroke patients. 
Furthermore, the aforementioned cardiac studies gener-
ally did not assess the impact of study pill adherence at 
various study time points, particularly at relatively early 
time points, such as within 6 months of study enroll-
ment.
 Traditionally, albeit arbitrarily, consumption of more 
than 80% of prescribed doses has been deemed an accept-
able level of adherence to therapy in various types of 
chronic illness  [5] . This cutoff point has been broadly 
Table 1. Frequencies of total study prescription pill adherence 
(before vascular event) by baseline covariates
Study pill adherence p
value
<80% ≥80% 
Age (years) 35–54 97 (18.9) 414 (81.0) 0.10
55–69 212 (15.9) 1,124 (84.1)
≥70 207 (14.9) 1,183 (85.1)
Sex female 220 (17.9) 1,010 (82.1) 0.02
male 296 (14.8) 1,711 (85.3)
Race white 347 (13.3) 2,268 (86.7) <0.0001
black 126 (27.8) 327 (72.2)
other 43 (25.4) 126 (74.6)
Current smoker yes 119 (22.4) 412 (77.6) <0.0001
no 397 (14.7) 2,308 (85.3)
BMI <25 141(15.7) 755 (84.3) 0.68
25–30 206 (15.5) 1,120 (84.5)
>30 165 (16.8) 815 (83.2)
Alcohol use yes 279 (14.6) 1,628 (85.4) 0.04
in prior year no 221 (17.3) 1,057 (82.7)
Stroke >90 days be- yes 168 (16.7) 836 (83.3) 0.41
fore randomization no 348 (15.6) 1,885 (84.4)
History of yes 371 (15.7) 1,999 (84.4) 0.45
hypertension no 144 (16.8) 715 (83.2)
History of yes 153 (16.7) 763 (83.3) 0.47
diabetes no 363 (15.7) 1,954 (84.3)
History of myo- yes 78 (15.2) 434 (84.8) 0.56
cardial infarction no 436 (16.1) 2,266 (83.9)
History of con- yes 23 (14.7) 133 (85.3) 0.61
gestive heart failure no 492 (16.1) 2,573 (83.9)
History of coronary yes 40 (12.8) 272 (87.2) 0.26
bypass surgery no 476 (16.3) 2,446 (83.7)
History of coronary yes 34 (15.3) 189 (84.8) 0.79
angioplasty no 482 (16.0) 2,527 (83.9)
History of carotid both 1 (3.5) 28 (96.6) 0.07
endarterectomy left 11 (11.1) 88 (88.9)
right 10 (11.2) 79 (88.8)
no 494 (16.4) 2,525 (83.6)
Any antithrombotic yes 309 (15.2) 1,728 (84.8) 0.12
use during trial no 207 (17.3) 993 (82.8)
Any statin use yes 283 (14.1) 1,721 (85.9) 0.0003
during the trial no 233 (18.9) 1,000 (81.1)
Data presented as number of patients with percentages in paren-
theses; p values refer to  high- vs. low-risk groups.
Total adherence was defined for each participant as: (visits 
>80% adherence/visits with adherence data) ! 100. Visit-specific 
adherence was calculated using the standard VISP definition as: 
[(pills dispensed at last visit – pills remaining)/days between last 
scheduled vitamin visit and today] ! 100.
Table 2. Frequencies of study prescription pill adherence (before 
vascular event) by study time point and primary endpoint
Occurrence of primary endpoint
yes no total adherence
6 months
<65% 9 (0.32) 74 (2.63) 83 (2.95)
65 to <80% 13 (0.46) 74 (2.63) 87 (3.09)
≥80 to <90% 34 (1.21) 187 (6.64) 221 (7.84)
≥90 to <99% 109 (3.87) 807 (28.64) 916 (32.51)
≥99% 159 (5.64) 1,352 (47.98) 1,511 (53.62)
Total 324 (11.50) 2,494 (88.50) 2,818 (100)
12 months
<65% 24 (0.86) 123 (4.41) 147 (5.27)
65 to <80% 19 (0.68) 73 (2.62) 92 (3.30)
≥80 to <90% 29 (1.04) 182 (6.56) 212 (7.60)
≥90 to <99% 75 (2.69) 773 (27.72) 848 (30.41)
≥99% 138 (4.95) 1,352 (48.48) 1,490 (53.42)
Total 285 (10.22) 2,504 (89.78) 2,789 (100)
18 months
<65% 27 (1.10) 112 (4.55) 139 (5.64)
65 to <80% 11 (0.45) 65 (2.64) 76 (3.08)
≥80 to <90% 26 (1.06) 128 (5.19) 154 (6.25)
≥90 to <99% 64 (2.60) 662 (26.87) 726 (29.46)
≥99% 106 (4.30) 1,263 (51.26) 1,369 (55.56)
Total 234 (9.50) 2,230 (90.50) 2,464 (100)
Data presented as number of patients with percentages in pa-
rentheses. Primary endpoint = Incidence of stroke, myocardial 
infarction, or vascular death.
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used in studies of patients with CAD, cancer, and hyper-
tension, and significantly linked to clinical outcomes  [5] . 
However, our results suggest that for stroke patients, non-
specific pill adherence  6 90% of the time, and not  6 80% 
of the time, is the cutoff point significantly linked to fa-
vorable outcomes. Indeed, in earlier studies of adherence 
to therapy in HIV-infected patients, the cutoff point of 
good adherence was the conventional 80% cutoff  [10–12] , 
but this changed  [13, 14] , after a landmark study showed 
that HIV-infected patients with 95% or greater adherence 
had superior outcomes than patients with lower levels of 
adherence, to the extent that the percentage of patients 
with a favorable outcome rose by 20% when adherence 
increased from 90–95% to 95–100%  [15] .
 Although the results of our study and those of others 
suggest a health benefit of adherence, the underlying 
mechanisms are not fully understood and the observa-
tional nature of these investigations limits any causal in-
ferences. Nonetheless, several potential mechanisms have 
been proposed to explain this association of good adher-
ence with favorable outcomes. For instance, it has been 
suggested that good adherence is a marker of a more gen-
eral predisposition to beneficial lifestyle practices such as 
healthy eating and regular physical activity, also known 
as the ‘healthy adherer effect’  [16] , while poor adherence 
has been associated with deleterious behaviors like smok-
ing. Indeed, one study found that adherence to a placebo 
pill was associated with a greater likelihood of consum-
ing a heart-healthy diet  [17] . Our study may also in part 
point to a general health-oriented behavior pattern as a 
potential explanation for the health benefits of adher-
ence, since like others we observed that current smokers 
in the VISP trial were less likely to adhere well to the VISP 
study pill regimen.
 Some have also suggested that psychosocial factors 
may contribute to the association of non-specific adher-
ence with clinical prognosis  [17] . This is because depres-
sion has been associated with poor adherence to cardiac 
medications  [18] , greater social support has been linked 
with better adherence  [19, 20] , and adherent subjects 
seem to engage in twice the number of pleasurable social 
activities before their index vascular event than poor ad-
herers  [17] . The latter finding has led some to believe that 
the relationship between good adherence and better out-
comes may simply reflect increased expectancy or belief 
in the prescribed regimen, in other words, a boosted pla-
cebo effect  [16] .
 There are potential practical and research implica-
tions to our results. Pending more definitive studies, the 
healthy adherer effect remains the foremost explanation 
Table 3. Cox proportional hazards model: pill adherence at 6 months vs. outcome
Hazard
ratio
95% confidence limits p value
lower limit upper limit
Age at first visit 1.03 1.02 1.04 <0.0001
Black race 1.27 0.91 1.78 0.17
Other race 1.59 1.01 2.51 0.05
Current smoker 0.97 0.65 1.45 0.89
Number of strokes prior to eligibility stroke 1.04 0.99 1.10 0.15
History of angina at visit 1 1.36 0.94 1.98 0.11
History of myocardial infarction at visit 1 1.44 1.05 1.98 0.03
History of congestive heart failure at visit 1 1.75 1.16 2.64 0.01
History of coronary artery bypass at visit 1 0.88 0.60 1.30 0.52
History of coronary angioplasty at visit 1 1.62 1.11 2.36 0.01
Systolic blood pressure at visit 1 1.01 1.00 1.01 0.06
Total cholesterol at visit 1 1.00 0.99 1.00 0.38
Any statin use during the trial 0.90 0.71 1.14 0.39
VISP high-dose vitamin treatment 0.99 0.79 1.24 0.94
VISP pill adherence: 65 to <80% 1.921 (1.68) 0.80 (0.71) 4.60 (3.97) 0.15 (0.24)
VISP pill adherence: ≥80 to <90% 1.841 (1.66) 0.86 (0.78) 3.93 (3.52) 0.12 (0.19)
VISP pill adherence: ≥90 to <99% 1.331 (1.23) 0.66 (0.61) 2.71 (2.47) 0.43 (0.56)
VISP pill adherence: ≥99% 1.141 (1.05) 0.56 (0.53) 2.29 (2.09) 0.72 (0.88)
Figures in parentheses contain unadjusted results. 1 Compared to level of adherence <65%. 
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Table 5. Cox proportional hazards model: pill adherence at 18 months vs. outcome
Hazard
ratio
95% confidence limits p value
lower limit upper limit
Age at first visit 1.02 1.01 1.04 0.002
Male sex 1.02 0.77 1.37 0.88
Black race 1.06 0.71 1.60 0.77
Other race 0.72 0.33 1.53 0.39
Current smoker 0.97 0.65 1.45 0.89
Number of strokes prior to eligibility stroke 1.05 1.00 1.12 0.12
History of angina at visit 1 1.39 0.90 2.16 0.14
History of myocardial infarction at visit 1 1.43 0.99 2.08 0.06
History of congestive heart failure at visit 1 1.87 1.16 3.01 0.01
History of coronary artery bypass at visit 1 0.88 0.57 1.38 0.59
History of coronary angioplasty at visit 1 1.57 1.01 2.46 0.05
Systolic blood pressure at visit 1 1.01 1.00 1.02 0.04
Total cholesterol at visit 1 1.00 0.99 1.004 0.67
Any statin use during the trial 1.12 0.84 1.50 0.44
VISP treatment 0.99 0.76 1.29 0.92
VISP pill adherence: 65% to <80% 0.771 (0.90) 0.35 (0.44) 1.68 (1.84) 0.51 (0.77)
VISP pill adherence: ≥80% to <90% 1.091 (1.07) 0.60 (0.61) 1.99 (1.88) 0.77 (0.81)
VISP pill adherence: ≥90% to <99% 0.561 (0.53) 0.34 (0.33) 0.91 (0.85) 0.02 (0.01)
VISP pill adherence: ≥99% 0.461 (0.45) 0.29 (0.29) 0.73 (0.71) 0.001 (0.001)
Figures in parentheses contain unadjusted results. 1 Compared to level of adherence <65%.
Table 4. Cox proportional hazards model: pill adherence at 12 months vs. outcome
Hazard
ratio
95% confidence limits p value
lower limit upper limit
Age at first visit 1.03 1.01 1.04 <0.0001
Male sex 1.10 0.85 1.43 0.47
Black race 1.01 0.69 1.47 0.97
Other race 1.16 0.67 2.02 0.59
Current smoker 1.13 0.80 1.60 0.48
Number of strokes prior to eligibility stroke 1.04 0.98 1.11 0.15
History of angina at visit 1 1.37 0.92 2.04 0.12
History of myocardial infarction at visit 1 1.25 0.88 1.77 0.22
History of congestive heart failure at visit 1 1.91 1.24 2.95 0.003
History of coronary artery bypass at visit 1 0.80 0.52 1.23 0.31
History of coronary angioplasty at visit 1 1.56 1.01 2.40 0.04
Systolic blood pressure at visit 1 1.01 1.00 1.01 0.02
Total cholesterol at visit 1 1.00 0.99 1.00 0.60
Any statin use during the trial 0.97 0.75 1.24 0.78
VISP treatment 0.99 0.78 1.26 0.92
VISP pill adherence: 65 to <80% 1.551 (1.36) 0.83 (0.74) 2.92 (2.51) 0.17 (0.32)
VISP pill adherence: ≥80 to <90% 0.941 (0.89) 0.53 (0.51) 1.67 (1.55) 0.83 (0.68)
VISP pill adherence: ≥90 to <99% 0.611 (0.57) 0.37 (0.35) 0.99 (0.91) 0.05 (0.02)
VISP pill adherence: ≥99% 0.611 (0.59) 0.38 (0.38) 0.98 (0.92) 0.04 (0.02)
Figures in parentheses contain unadjusted results. 1 Compared to level of adherence <65%.
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for the association of good pill prescription adherence 
with beneficial outcomes  [5] . As such, it may be useful 
and not necessarily laborious for clinicians to use compli-
ance with the prescribed drug regimen by their stroke 
patients as an indicator of overall adherence to a healthy 
lifestyle. Those individuals who are noted to adhere poor-
ly to prescribed drugs may benefit from more extensive 
inquiry into various aspects of their lifestyle, in order to 
uncover potentially unhealthy behaviors and provide ad-
ditional education/counseling. Another practical consid-
eration is that practitioners might consider using compli-
ance with the prescribed drug regimen by their stroke 
patients to target those persons with underlying un-
healthy psychosocial issues that may need to be resolved 
in order to enhance clinical outcomes. In the research 
arena, information on study-blinded prescription pill ad-
herence in randomized secondary stroke prevention tri-
als may be considered along with the usual sociodemo-
graphic and clinical prognosticator variables to further 
ensure that randomization was actually balanced.
 The association between excellent adherence and fa-
vorable clinical outcomes at longer time points (12 and 18 
months) but not at the shorter time point of 6 months has 
not been examined in prior studies exploring this issue, 
but this result seems plausible. Patients are generally 
much more focused on the index vascular event early af-
ter it occurs, and are thereby more likely to be compliant 
with the medical recommendations during relatively ear-
ly periods as opposed to later on  [4] . This may be further 
buttressed by our finding of a stronger association of ex-
cellent study pill adherence with outcomes at 18 months 
compared to 12 months.
 Our study has limitations. As noted, it was observa-
tional and so no causal inferences can be made. Although 
we conducted a multivariable analysis, unmeasured con-
founding could still explain our results. Adherence was 
measured by pill count, which may overestimate adher-
ence since subjects may not ingest all the pills they re-
move from a bottle  [21] . It must also be pointed out that 
there is a limit on the extent to which we can generalize 
data from the VISP population, because it is conceivable 
that since VISP patients were encountered in a research-
oriented setting, they were probably more motivated than 
stroke survivors seen in routine medical practice, and so 
pill adherence rates in the latter setting may be much 
worse. Finally, the post hoc nature of the study meant we 
could only examine the variables collected in the original 
study, which limited the exploration of the contribution 
of lifestyle practices and psychosocial factors to the asso-
ciations we observed  [5] .
 In conclusion, we found longer-term excellent adher-
ence to pill prescription among persons who have recent-
ly experienced a recent ischemic stroke to be indepen-
dently associated with lower risk of subsequent vascular 
events. Our results need to be confirmed independently, 
and the possibility of a causal relation between adherence 
and health outcomes investigated. However, in the mean-
time, clinicians may consider adherence to pill prescrip-
tion as a potential marker of overall healthy behavior, 
which could be used in targeting stroke patients with un-
healthy lifestyle practices that need to be addressed.
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